Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

http://www.wikidata.org/entity/Q35015882

about

Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study Profile of conbercept in the treatment of neovascular age-related macular degeneration.A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Recent perspectives on the delivery of biologics to back of the eye.Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury.Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report.Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.Stanniocalcin-1 rescued photoreceptor degeneration in two rat models of inherited retinal degeneration.Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution.The efficacy and safety of aflibercept and conbercept in diabetic macular edema

P2860

Q33759212-08486DA0-22B3-45F6-8B9D-78B7FC99F8B5 Q33912465-C0765C5B-A28F-4430-AF73-1EA2960FB1D7 Q34658699-8AA64D15-2F0F-4DFA-B705-D3FDC8B9020C Q34740219-7AFFE4F9-65AD-433A-89AD-3F0F8073998A Q35166714-08BBAE60-3CB3-4D22-B053-F9462193AE0D Q35541714-8793E978-9EE7-4D11-A991-8EC0134D12DB Q36731129-B24A2EA2-8951-42A3-AC23-074FD63AEF5D Q36752250-11F0FD1B-2FE0-4F74-B3E7-B8CFBA7B9E56 Q37070754-496D1FB7-EEDC-4D3F-B10E-174A8CB20F61 Q37133086-A1C46C82-0F81-4974-A513-9F5B67138BB2 Q37455178-7A7FFB62-CCF8-49ED-9031-C9561B74DF3A Q37549985-AB64CF8F-824E-4742-ABEF-80E1E8BD09AB Q38183850-6D3C3B89-C851-4445-BECA-9EF81D880EA7 Q38940171-940C8967-C575-4FCB-88B4-37C301C8CA79 Q41458017-AE6A438A-44CE-401E-BCC3-9CEE3EF45114 Q41837052-9E57146B-9A34-4DED-8F70-43F386F3C8E3 Q41925040-7F127F55-0301-488A-87CF-1E8E41952DC4 Q41974923-69188139-4B6E-4977-B653-56A64D5A9899 Q41975515-EBC34D01-6B7A-4028-BBE8-FFE66F7BAFDB Q58562047-4C52BA2B-9233-411F-A2EB-11ACF758B424

P2860

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

http://www.wikidata.org/entity/Q35015882

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@ast

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@en

type

label

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@ast

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@en

prefLabel

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@ast

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@en

P1433

Q35015882-F315903A-2280-4967-98A8-0EF85291C8F0

P1476

Q35015882-D5EF28AB-3DC3-4B2D-BFA8-804C1DCE1243

P2093

Q35015882-0E8062A9-F6AC-40C2-9295-EE7CA373A52F

Q35015882-0EF05C01-B55E-47F6-A196-C9FB0269EAF7

Q35015882-1A77A37C-BAA4-432E-9671-30E4B4D0F65A

Q35015882-1E1DC0DD-F78F-44A7-B408-993B21203E90

Q35015882-2D89E77D-AEB8-4447-BFF2-C0D624D3E159

Q35015882-39BD3DF8-E87B-491D-BEFD-491F512184C4

Q35015882-53AF73AB-86FD-4C16-B3D0-A46DC14C4ACC

Q35015882-76B6B617-8C94-43E2-B950-3014D9B4074D

Q35015882-CD449EC2-F0B5-4A19-95BE-17871E8142A0

P2860

Q35015882-0BB38ABB-49F9-48AA-A8CF-F413279BF9DC

Q35015882-0E6187FF-9467-427A-88F1-81B7F55FA61A

Q35015882-144556A3-8332-48A0-9123-98875ACEDD59

Q35015882-15E7E9C5-C718-4A1C-B002-3351BB639D7D

Q35015882-23259113-30F7-492E-8D29-B3165C3458A9

Q35015882-2350A848-B70C-4F9C-8AB9-3097EB28AAA5

Q35015882-24D66737-164C-4E35-9924-3E1A97DBB04A

Q35015882-32478DAE-0DFF-4BA9-9B53-E2171088FED1

Q35015882-6AF4254D-8F15-4829-A84B-C91D749C0943

Q35015882-714BB6A7-9819-4753-A487-8322928DDC04

P304

Q35015882-BFD2DD5F-3A5C-456F-8EDF-3616CCC403B2

P31

Q35015882-4FFDD40E-41BE-447D-8C4B-F6B52B79E8FB

P356

Q35015882-11B239D0-C404-4AD6-A833-358D3EE52716

P407

Q35015882-1B36BEC7-EEA7-46F6-8015-71769ECE35AF

P478

Q35015882-291DFC89-7B51-497B-B73C-8C0253AE2597

P50

Q35015882-2D887820-53C9-4990-979F-BAF66014BB08

P577

Q35015882-0493AA6B-B998-49AB-A576-105B3C06E6BD

P698

Q35015882-EC9DCC39-7CF6-46AC-9EE9-7E74CF5CCDF7

P921

Q35015882-324107FD-B917-4F73-AAC9-564D6350309D

P932

Q35015882-9693864F-9DFA-4297-BEA5-1A4A9B98697C

P356

P1433

Clinical Ophthalmology

P1476

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

@en

P2093

Alkistis Pantopoulou

http://www.w3.org/2001/XMLSchema#string

Angelos I Sinapis

http://www.w3.org/2001/XMLSchema#string

Christos I Sinapis

http://www.w3.org/2001/XMLSchema#string

Despoina Perrea

http://www.w3.org/2001/XMLSchema#string

Dimitrios I Sinapis

http://www.w3.org/2001/XMLSchema#string

Efstratios Patsouris

http://www.w3.org/2001/XMLSchema#string

George D Agrogiannis

http://www.w3.org/2001/XMLSchema#string

Stamatis E Theocharis

http://www.w3.org/2001/XMLSchema#string

Stefanos Baltatzis

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

P304

697-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S19555

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

John G Routsias

P577

2011-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21629577

http://www.w3.org/2001/XMLSchema#string

P921

P932

3104800

http://www.w3.org/2001/XMLSchema#string